Fresenius Kabi (thailand) Ltd Pharmaceutical Import Profile — Thailand (DGFT 2022–2026)

Name: Fresenius Kabi (thailand) Ltd Pharmaceutical Import Records from India — 7 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi (thailand) Ltd — Pharmaceutical Importer Profile (2026) | 7 Products, $5.0M Trade | TransData Nexus

Fresenius Kabi (thailand) Ltd

Pharmaceutical Importer · Thailand · Oncology Focus · $5.0M Total Trade · DGFT Verified

Fresenius Kabi (thailand) Ltd is a pharmaceutical importer based in Thailand with a total trade value of $5.0M across 7 products in 2 therapeutic categories. Based on 112 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi (thailand) Ltd sources from 2 verified Indian suppliers, with Fresenius Kabi Oncology Limited accounting for 94.8% of imports.

Fresenius Kabi (thailand) Ltd — Import Portfolio & Supplier Network

Fresenius Kabi (thailand) Ltd import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi (thailand) Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$1.8M	52	94.8%
Fresenius Kabi India Private Limited	$100.0K	4	5.2%

Fresenius Kabi (thailand) Ltd sources from 2 verified Indian suppliers across 45 distinct formulations.

What Formulations Does Fresenius Kabi (thailand) Ltd Import?

Formulation	Value	Ships
Kemoplat cisplatin INJ 50MG 50ML vial batch no 87230068aa mfg dt 02 2023 exp dt 01	$105.4K	4
Oxitan oxaliplatin INJ 50MG 10ML vial batch no 87230082ab 87230083aa mfg dt 02 2023 exp dt 01	$100.0K	2
Oxitan oxaliplatin INJ 100MG 20ML vial batch no 87230075aa 87230074ab mfg dt 02 2023 exp dt 01	$100.0K	2
Intaxel paclitaxel USP INJ 300MG 50mlvial batch no 87230064aa mfg dt 02 2023 exp dt 01	$100.0K	2
Irinotel irinotecan hcl INJ 100MG 5ML vial batch no 87230069ab mfg dt 02 2023 exp dt 01	$81.0K	2
Gemita gemcitabine USP INJ 200MG vial batch no 87230050ab mfg dt 01 2023 exp dt 12	$66.2K	2
Human medicines-metronidazole	$50.0K	1
Intaxel paclitaxel USP INJ 300MG 50mlvial batch no 87230052ba mfg dt 01 2023 exp dt 12	$50.0K	1
Kemocarb carboplatin BP INJ 450MG 45ML vial batch no 87230071aa mfg dt 02 2023 exp dt 01	$50.0K	1
Adrim doxorubicin INJ USP 50MG 25ML vial batch no 87230085aa 87230086ad 87230063aa mfg dt 02 2023 exp dt 07	$50.0K	1
Kemocarb carboplatin BP INJ 450MG 45ML vial batch no 87230072ab mfg dt 02 2023 exp dt 01	$50.0K	1
Oxitan oxaliplatin INJ 100MG 20ML vial b no 87230076aa 87230077aa mfg dt 02 2023 exp dt 01	$50.0K	1
Adrim doxorubicin INJ. USP 50MG/25ML vial bno. 87230277aa, manufacturing . dt. 06/2023,exp. dt.	$50.0K	1
Kemocarb carboplatin BP INJ. 450MG/45ML vial bno. 87230291ab, manufacturing . dt. 06/2023, exp. dt.	$50.0K	1
Human medicine-metronidazole injection USP 0.5% w/v 100ML eurohead [1 x 50	$50.0K	1

Fresenius Kabi (thailand) Ltd imports 45 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gemcitabine	Oncology	$1.3M	34	1.5%	14
2	Carboplatin	Oncology	$1.2M	24	0.9%	7
3	Oxaliplatin	Advanced Oncology	$1.0M	20	1.4%	6
4	Paclitaxel	Oncology	$600.0K	12	0.4%	14
5	Docetaxel	Oncology	$440.8K	9	1.1%	17
6	Cisplatin	Oncology	$300.0K	6	2.3%	7
7	Cytarabine	Advanced Oncology	$211.5K	7	2.0%	15

Fresenius Kabi (thailand) Ltd imports 7 pharmaceutical products across 2 categories into Thailand totaling $5.0M.

Fresenius Kabi (thailand) Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi (Thailand) Ltd is a subsidiary of the global healthcare company Fresenius Kabi, which specializes in essential medicines and technologies for infusion, transfusion, and clinical nutrition. Established in 1999, Fresenius Kabi has become a key player in the field of nutrition and infusion therapy, offering a comprehensive range of products and services for hospitals and patients at home.

Headquartered in Bangkok, Thailand, Fresenius Kabi (Thailand) Ltd operates as a pharmaceutical importer and distributor, focusing on the procurement and distribution of finished pharmaceutical formulations. The company's role in Thailand's pharmaceutical distribution network involves sourcing a variety of pharmaceutical products, including oncology medications, and ensuring their availability to meet the needs of healthcare providers and patients across the country.

2Distribution Network

Fresenius Kabi (Thailand) Ltd's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Thailand. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are robust, enabling timely and reliable distribution to various regions within the country. This infrastructure supports the company's mission to provide essential medicines and medical devices to healthcare institutions and patients nationwide.

3Industry Role

In Thailand's pharmaceutical supply chain, Fresenius Kabi (Thailand) Ltd functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from international suppliers, including those in India, and facilitates their entry into the Thai market. By doing so, Fresenius Kabi (Thailand) Ltd plays a crucial role in ensuring the availability of a diverse range of pharmaceutical products, particularly in specialized therapeutic areas such as oncology, thereby supporting the healthcare system's capacity to address various medical needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi (thailand) Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi (Thailand) Ltd's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a limited number of suppliers. Notably, the company has imported approximately $1.8 million worth of products from Fresenius Kabi Oncology Limited, accounting for 94.8% of its total shipments from India. This concentration suggests a strategic partnership aimed at ensuring product quality and supply chain reliability. However, such dependency also introduces potential risks, including supply disruptions or changes in supplier terms. The stability of this relationship is critical for maintaining uninterrupted access to essential pharmaceutical products in the Thai market.

2Supply Chain Resilience

The resilience of Fresenius Kabi (Thailand) Ltd's supply chain is closely tied to its reliance on a limited number of suppliers, particularly Fresenius Kabi Oncology Limited. While this focused sourcing strategy may enhance consistency and quality control, it also exposes the company to risks associated with supply chain disruptions, such as production delays or geopolitical issues affecting supplier operations. To mitigate these risks, it is essential for Fresenius Kabi (Thailand) Ltd to develop contingency plans, including identifying alternative suppliers and diversifying its product portfolio to ensure a steady supply of critical pharmaceutical products to the Thai market.

Importing Pharmaceuticals into Thailand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Thailand

1Regulatory Authority & Framework

In Thailand, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA's responsibilities include ensuring that all drugs imported into the country are registered and comply with established safety and efficacy standards. The regulatory framework governing pharmaceutical imports is outlined in the Drugs Act B.E. 2510 (1967) and its subsequent amendments, which stipulate the procedures and requirements for drug registration, importation, and distribution. (en.fda.moph.go.th)

2Import Licensing & GMP

Import licensing requirements in Thailand mandate that all pharmaceutical products, including finished formulations, must be registered with the FDA prior to importation. This process involves submitting comprehensive documentation to demonstrate the product's safety, efficacy, and quality. Additionally, the FDA recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to facilitate the importation process. (en.fda.moph.go.th)

Quality & Labeling

Fresenius Kabi (thailand) Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi (Thailand) Ltd's focus on importing oncology medications aligns with the growing demand for cancer treatments in Thailand. The Thai population is experiencing an increase in cancer incidence, necessitating a reliable supply of effective therapies. By concentrating on this therapeutic area, the company addresses a critical healthcare need, positioning itself as a key contributor to improving patient outcomes in oncology.

2Sourcing Profile

Fresenius Kabi (Thailand) Ltd's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology sector. The company imports finished pharmaceutical formulations from suppliers that hold recognized GMP certifications, ensuring product quality and regulatory compliance. India plays a significant role in this strategy, serving as a primary source for these generic formulations due to its established reputation in pharmaceutical manufacturing.

3Market Positioning

Based on its product mix, Fresenius Kabi (Thailand) Ltd primarily serves the hospital segment of the Thai market. By supplying essential oncology medications, the company supports healthcare institutions in providing critical care to cancer patients. Additionally, the company's involvement in importing and distributing pharmaceutical products positions it to participate in government tenders, further solidifying its presence in the healthcare sector.

Seller's Guide — How to Become a Supplier to Fresenius Kabi (thailand) Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Thai market by partnering with Fresenius Kabi (Thailand) Ltd. The company's concentrated sourcing pattern indicates a potential openness to diversifying its supplier base. Indian exporters can explore this opportunity by offering high-quality products, competitive pricing, and adherence to international quality standards. Identifying gaps in the current sourcing strategy, such as unmet demand for specific formulations or therapeutic areas, can further enhance the attractiveness of new suppliers.

2Requirements & Qualifications

Indian exporters seeking to supply Fresenius Kabi (Thailand) Ltd and the broader Thai market must ensure that their products are registered with the Thai FDA and comply with the regulatory requirements outlined in the Drugs Act B.E. 2510 (1967) and its amendments. Additionally, holding valid GMP certifications from recognized bodies such as EU GMP, WHO GMP, or PIC/S is essential to facilitate the importation process. Products must also meet labeling requirements, including full translation into the Thai language, and adhere to batch testing and stability standards. (en.fda.moph.go.th)

How to Approach

Frequently Asked Questions — Fresenius Kabi (thailand) Ltd

What products does Fresenius Kabi (thailand) Ltd import from India?

Fresenius Kabi (thailand) Ltd imports 7 pharmaceutical products across 2 categories. Top imports: Gemcitabine ($1.3M), Carboplatin ($1.2M), Oxaliplatin ($1.0M), Paclitaxel ($600.0K), Docetaxel ($440.8K).

Who supplies pharmaceuticals to Fresenius Kabi (thailand) Ltd from India?

Fresenius Kabi (thailand) Ltd sources from 2 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (94.8% of imports, $1.8M).

What is Fresenius Kabi (thailand) Ltd's total pharmaceutical import value?

Fresenius Kabi (thailand) Ltd's total pharmaceutical import value from India is $5.0M, based on 112 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi (thailand) Ltd focus on?

Fresenius Kabi (thailand) Ltd imports across 2 categories. The largest: Oncology (75.9%), Advanced Oncology (24.1%).

Get Full Fresenius Kabi (thailand) Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.